FindMyKOL

Samer Kasbari, MD, MS

Basic profile

Southeastern Medical Oncology Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionGoldsboro, NC · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLEmergingFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Samer Kasbari is an Oncology physician affiliated with Southeastern Medical Oncology Center. OpenAlex indexes 22 publications with 815 citations (h-index 9).

Overview

Scholarship

indexed output and impact (OpenAlex)
22publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

815citations

Citations across these publications.

9h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
61companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Novartis Pharmaceuticals Corporation
    Program year202514 payments
    $1,035
  • Eisai Inc.
    Program year20255 payments
    $116
  • Janssen Biotech, Inc.
    Program year20254 payments
    $100
All 116 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    40.9%
    PD-1 inhibitor25%
    Pembrolizumab51%Nivolumab48%Keytruda0%Tecentriq0%
    Part D + Part B<11 patients
    Platinum-based Drug14.2%
    Oxaliplatin98%Carboplatin2%
    Part B, office-administered≥17 patients

    + 9 more classes in this area

  • Blood & clotting

    25.8%
    Erythropoiesis-stimulating Agent17.7%
    Darbepoetin alfa100%
    Part B, office-administered≥19 patients
    Iron, parenteral preparations7.9%
    Ferric derisomaltose100%
    Part B, office-administered≥58 patients

    + 2 more classes in this area

  • Musculoskeletal

    17.8%
    RANK Ligand Inhibitor17.5%
    Denosumab100%Prolia1%
    Part D + Part B≥147 patients
    Bisphosphonate0.4%
    Zoledronic acid100%
    Part B, office-administered≥49 patients
Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”